Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases


Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.blueprintmedicines.com

Recent News

March 20, 2017
Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667

March 9, 2017
Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results

March 2, 2017
Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017

Read More News

Associated Team Members

Alexis Borisy
Partner

Neil Exter
Partner